Tsumura & Co. (TSMRF)
ValueMarkers Composite Index
DCF data not available
Tsumura & Co. (TSMRF) — VMCI valuation read
TSMRF prints VMCI 65/100 inside the Healthcare sector, where the median sits at 50. The 15-point above-median delta is the cleanest single-number summary of Tsumura & Co.'s composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On TSMRF, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** TSMRF trades at 18.0x earnings, 0% above the Healthcare median of 18.0x; that is the value line. ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 2.3x is the rate-sensitivity line to watch; that is the risk line for Tsumura & Co. on the trailing financials.
TSMRF rose 0.8% over the trailing 7 days, with a -1.6% read on a 30-day basis.
Tsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines; and sale of pharmaceuticals and food products. The company was founded in 1893 and is headquartered in Tokyo, Japan.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.